MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

Search

Cytek Biosciences Inc

Закрыт

СекторЗдравоохранение

5.39 -3.92

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

5.38

Макс.

5.48

Ключевые показатели

By Trading Economics

Доход

105K

-5.5M

Продажи

6.7M

52M

Прибыль на акцию

-0

Рентабельность продаж

-10.476

Сотрудники

692

EBITDA

6.4M

-4.2M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+10.97% upside

Дивиденды

By Dow Jones

Следующий отчет о доходах

26 февр. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

240M

742M

Предыдущая цена открытия

9.31

Предыдущая цена закрытия

5.39

Новостные настроения

By Acuity

17%

83%

18 / 361 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Weak Bullish Evidence

Cytek Biosciences Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

16 янв. 2026 г., 23:29 UTC

Популярные акции

Stocks to Watch: Atossa Therapeutics, Union Pacific

16 янв. 2026 г., 22:48 UTC

Приобретения, слияния, поглощения

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- 2nd Update

16 янв. 2026 г., 22:43 UTC

Приобретения, слияния, поглощения

Union Pacific: Additional Information Requested to Be Provided to Surface Transportation Board

16 янв. 2026 г., 22:22 UTC

Приобретения, слияния, поглощения

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- Update

16 янв. 2026 г., 21:50 UTC

Обсуждения рынка
Приобретения, слияния, поглощения

Tech, Media & Telecom Roundup: Market Talk

16 янв. 2026 г., 21:50 UTC

Обсуждения рынка
Приобретения, слияния, поглощения

Auto & Transport Roundup: Market Talk

16 янв. 2026 г., 21:50 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

16 янв. 2026 г., 21:50 UTC

Обсуждения рынка

Health Care Roundup: Market Talk

16 янв. 2026 г., 21:48 UTC

Обсуждения рынка
Приобретения, слияния, поглощения

Union Pacific, Norfolk Southern Market Share Ruled as Faulty -- Market Talk

16 янв. 2026 г., 21:41 UTC

Обсуждения рынка
Приобретения, слияния, поглощения

Union Pacific, Norfolk Southern Deal Rejection Leaves Questions -- Market Talk

16 янв. 2026 г., 21:38 UTC

Приобретения, слияния, поглощения

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- WSJ

16 янв. 2026 г., 21:30 UTC

Приобретения, слияния, поглощения

STB: Union Pacific, Norfolk Southern Application Doesn't Include 'Projected Market Shares' as Required

16 янв. 2026 г., 21:30 UTC

Приобретения, слияния, поглощения

STB: Union Pacific, Norfolk Southern Application Doesn't Include Certain Schedules, Documents Expressly Made Part of Merger Agreement

16 янв. 2026 г., 21:30 UTC

Приобретения, слияния, поглощения

STB: Union Pacific, Norfolk Southern Application Doesn't Contain Certain Information Required by Regulations

16 янв. 2026 г., 21:30 UTC

Приобретения, слияния, поглощения

STB: Application Rejected Without Prejudice to Union Pacific, Norfolk Southern Refiling Revised Application Remedying Deficiencies

16 янв. 2026 г., 21:30 UTC

Приобретения, слияния, поглощения

Surface Transportation Board: Union Pacific, Norfolk Southern Major Merger Application Filed Dec. 19 Incomplete

16 янв. 2026 г., 20:44 UTC

Отчет

5 Takeaways From This Season's Wealth Management Earnings -- Barrons.com

16 янв. 2026 г., 20:42 UTC

Обсуждения рынка

Oil Futures Post Fourth Straight Weekly Gain -- Market Talk

16 янв. 2026 г., 20:28 UTC

Обсуждения рынка

U.S. Natural Gas Slips Ahead of Long Weekend -- Market Talk

16 янв. 2026 г., 19:12 UTC

Обсуждения рынка
Приобретения, слияния, поглощения

Netflix Could Comment on Structure of Warner Bid During 4Q Results -- Market Talk

16 янв. 2026 г., 18:53 UTC

Обсуждения рынка

Global Crude Supply Enough to Absorb Any Iran Disruption -- Market Talk

16 янв. 2026 г., 18:41 UTC

Обсуждения рынка

Netflix's Ad Business Seen as Primary Revenue Driver in 2026 -- Market Talk

16 янв. 2026 г., 18:31 UTC

Обсуждения рынка

U.S. Oil Rig Count Rises By 1 to 410 -- Market Talk

16 янв. 2026 г., 17:20 UTC

Обсуждения рынка

Financial Services Roundup: Market Talk

16 янв. 2026 г., 17:20 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

16 янв. 2026 г., 17:20 UTC

Обсуждения рынка

Health Care Roundup: Market Talk

16 янв. 2026 г., 17:03 UTC

Обсуждения рынка

Global Equities Roundup: Market Talk

16 янв. 2026 г., 17:03 UTC

Обсуждения рынка

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

16 янв. 2026 г., 16:32 UTC

Обсуждения рынка
Приобретения, слияния, поглощения

Sanofi Needs Dealmaking to Offset Pipeline Disappointments -- Market Talk

16 янв. 2026 г., 16:20 UTC

Обсуждения рынка

Global Equities Roundup: Market Talk

Сравнение c конкурентами

Изменение цены

Cytek Biosciences Inc Прогноз

Целевая цена

By TipRanks

10.97% рост

Прогноз на 12 месяцев

Средняя 6.17 USD  10.97%

Максимум 7.5 USD

Минимум 5 USD

Основано на мнении 3 аналитиков Wall Street, спрогнозировавших целевые цены для Cytek Biosciences Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

3 ratings

2

Покупка

1

Удержание

0

Продажа

Техническая оценка

By Trading Central

3.7 / 3.8Поддержка и Сопротивление

Краткосрочная

Weak Bullish Evidence

Среднесрочная

Bearish Evidence

Долгосрочная

Bearish Evidence

Настроения

By Acuity

18 / 361Рейтинг в Здравоохранение

Новостные настроения

Сильные свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Средняя

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Cytek Biosciences Inc

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
help-icon Live chat